Get Premium to unlock powerful stock data
FRA:PHPN (USA)  
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc

€ 1.24 (+0.81%) Jul 4
P/E:
At Loss
P/B:
0
Market Cap:
€ 74.58M ($ 76.58M)
Enterprise V:
€ 74.51M ($ 76.51M)
Volume:
-
Avg Vol (2M):
400.00
Also Trade In:
Volume:
-
Market Cap €:
74.58M
Market Cap $:
76.58M
PE Ratio:
At Loss
Avg Vol (2-Month):
400.00
Enterprise Value €:
74.51M
Enterprise Value $:
76.51M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Galectin Therapeutics Inc
NAICS : 325412 SIC : 2834
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Name Current Vs Industry Vs History
Cash-To-Debt 1.08
Equity-to-Asset -0.18
Debt-to-Equity -4.73
Debt-to-EBITDA -0.88
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -14.2
3-Year EPS without NRI Growth Rate -11
3-Year FCF Growth Rate -17.2
Name Current Vs Industry Vs History
5-Day RSI 63.94
9-Day RSI 52.6
14-Day RSI 49.5
6-1 Month Momentum % -32.18
12-1 Month Momentum % -50.36

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.51
Quick Ratio 3.51
Cash Ratio 3.31

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.9
Name Current Vs Industry Vs History
ROE % -417.76
ROA % -100.49
ROIC % -6371.98
ROC (Joel Greenblatt) % -50800.91
ROCE % -126.43

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -2.34
EV-to-EBITDA -2.34
EV-to-FCF -2.99
Earnings Yield (Greenblatt) % -42.74

Financials (Next Earnings Date:2022-08-16 Est.)

FRA:PHPN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0
EPS (TTM) (€) -0.504
Beta 1.06
Volatility % 68.71
14-Day RSI 49.5
14-Day ATR (€) 0.049621
20-Day SMA (€) 1.251
12-1 Month Momentum % -50.36
52-Week Range (€) 1.1 - 3.76
Shares Outstanding (Mil) 59.39

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Galectin Therapeutics Inc Filings

Document Form Filing Date
No Filing Data